Clinical and laboratory data of patients with diabetic foot ulcers who complete the follow-up study at the terminal of long term follow-up study
| Thrombolysis therapy (n=69) | Conventional therapy (n=48) | |
| TC (mmol/L) | 4.8 (1.1) | 5.1 (0.8)* |
| LDL-C (mmol/L) | 2.5 (0.6) | 3.0 (0.8)* |
| HDL-C (mmol/L) | 1.3 (0.3) | 1.3 (0.3) |
| TG (mmol/L) | 1.6 (0.5) | 2.1 (1.0)* |
| FBG (mmol/L) | 7.8 (1.6) | 8.9 (1.0)* |
| 2-hour BG (mmol/L) | 9.5 (1.5) | 12.7 (2.0)* |
| Fibrinogen (g/L) | 4.7 (0.9) | 5.0 (1.1) |
| TBP | 63.4 (16.9) | 55.3 (13.2) |
| TBI | 0.4 (0.1) | 0.3 (0.1) |
| ABI | 1.2 (0.2) | 1.0 (0.3) |
| TcPO2 (mm Hg) | 44.8 (15.8) | 40.1 (14.4)* |
| Peripheral neuropathy | 28 (28.6%) | 48 (49.5%)* |
| NDS | 4.9 (3.2) | 6.7 (3.5)* |
Data are number (%), mean (SD).
All results were from analyses adjusted for baseline.
*P<0.05.
ABI, ankle-brachial index; BG, blood glucose; FBG, fasting blood glucose; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; NDS, Neuropathy Deficit Score; TBI, toe brachial index; TBP, toe blood pressure; TC, total cholesterol; TcPO2, transcutaneous oxygen tension; TG, triacylglycerol.